In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

Despite constraints exerted by GLP-1RAs on bariatric surgery volumes, shares in Intuitive Surgical surged following a ...

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.